Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Orthofix Medical Earnings Call: Key Takeaways

Orthofix reported a challenging Q3 2026, missing internal expectations due to US Spine market softness and supplier delays, leading to a downward revision of full-year revenue and EBITDA guidance.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthLimb Reconstruction 9%, Therapeutic Solutions 4%, Global Spine -1%, US Spine -5%.
Mgmt ConfidenceCautious; acknowledged Q3 results were below expectations and supply chain issues persist.
Demand VisibilityLimited; cited unplanned supplier delays and inventory constraints impacting top 30 distributors.
Margin TrendsAdjusted gross margin 70.7%; EBITDA margin 12.5% vs 12.1% prior year.
Op. LeverageReduced operating leverage noted due to lower spine revenue and unfavorable mix.
Vol vs PriceTherapeutic Solutions saw 4% volume growth; Spine growth impacted by inventory constraints.
Segment GrowthLimb Reconstruction outperforming at 9%; US Spine Fixation lagging at -5%.
New ClientsConcentrating resources on top distributors generating 80% of US spinal implant revenue.
Capex & DebtEnded quarter with $86.9M cash; inventory investment ahead of Bharata launch.
RegulatoryTwo 510K clearances for 7D navigation; $22M 2027 headwind from European MDR.
CommentaryStrategy focuses on simplifying portfolio and exiting non-strategic, lower-performing distributor relationships.
New LaunchesFull market launch of Bharata spinal implant system expected in Q4 2026.

Growth

Reported net sales of $207.9M, up 2.3% year-over-year; Limb Reconstruction grew 9% constant currency.

Outlook

Full-year 2026 revenue guidance lowered to $825M-$830M; $22M MDR headwind expected in 2027.

Risks

Management pivoted to vague 'market softness' language when pressed on market share loss versus procedural declines.

Source

The company's earnings call, NASDAQ: OFIX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Orthofix Medical Inc.: key numbers

Share price
$6.80Close, Nov 16
Market cap
$277M
Shares outstanding
40.76MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Orthofix Medical Inc.

All →
5:39 PM ET Form 4
Insider Buying

Orthofix Medical Insider Juniper Investment Company LLC Buys $5.11M of Stock

Juniper Investment Company LLC bought 689,803 shares of Orthofix Medical Inc. at $7.04 to $7.41 a share (average $7.40) in 2 transactions, worth $5.11M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 4,461,019 (+0.3%).

Value
$5.11M
Shares
689,803
Average price
$7.40
Holding change
+0.3%
Trade date
Nov 9, 2026 to Nov 11, 2026
8:04 AM ET 10-Q
Financial Results ▶ Call

Orthofix Medical Q3 2026 Results: Net Loss of $6.07M, Loss Narrows

Orthofix Medical Inc. reported net sales of $207.9 million for the third quarter of 2026, a slight increase from $205.6 million in the prior year period. The company achieved a quarterly operating income of $1.5 million, a significant improvement from the $17.0 million operating loss in Q3 2025, though it still recorded a net loss of $6.1 million for the quarter.

Key figure
Net loss $6.07M
8:01 AM ET 8-K
Financial Results

Orthofix Medical Financial Results

Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 1% increase over the prior year, and a net loss of $6.1 million. The company revised its full-year 2026 revenue guidance downward to $825M-$830M to reflect weaker performance in its U.S. Spine business and ongoing efforts to improve commercial execution.

Term
Q3 2026

“Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance. In U.S. Spine, we are accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity by focusing resources on our highest-performing distributor partners, products and market opportunities.”

Massimo Calafiore, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.